Cantor Fitzgerald Brokers Lower Earnings Estimates for BCAX

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Bicara Therapeutics in a research note issued to investors on Wednesday, May 14th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings per share of ($2.11) for the year, down from their prior estimate of ($1.81). Cantor Fitzgerald currently has a “Overweight” rating and a $13.01 price objective on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Several other equities research analysts have also issued reports on BCAX. HC Wainwright decreased their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating on the stock in a report on Friday. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a report on Thursday, March 27th. Finally, Wells Fargo & Company began coverage on Bicara Therapeutics in a report on Thursday, April 17th. They set an “underweight” rating and a $8.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX opened at $14.47 on Friday. Bicara Therapeutics has a 12 month low of $8.91 and a 12 month high of $28.09. The stock has a 50-day moving average price of $12.81 and a two-hundred day moving average price of $15.25.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.28).

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth $25,000. CWM LLC bought a new position in Bicara Therapeutics during the 1st quarter worth $29,000. Spire Wealth Management acquired a new position in Bicara Therapeutics during the 4th quarter worth about $31,000. BNP Paribas Financial Markets acquired a new position in Bicara Therapeutics during the 4th quarter worth about $32,000. Finally, Legal & General Group Plc bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $33,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.